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ABSTRACT Non-syndromic cleft lip with or without cleft 
palate (NSCLP) is a congenital malformation that shows 
the characteristics of a multifactorial pathology. In order 
to describe the genetic predisposition to this disorder, NAT 
genes were analyzed with special interest since they codify 
for N-acetyltransferases, the enzymes responsible for the bi-
otransformation of arylamines, hydrazine drugs and a great 
number of toxins and carcinogens present in diet, cigarette 
smoke and the environment. The allelic transmission of 
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NAT2 that determines the slow acetylator phenotype in 174 
trios (case-mother/father) from ECLAMC (Latin American 
Collaborative Study of Congenital Malformations) materni-
ties in Argentina was evaluated. The *4, *5B, *6, and *7 
variants by PCR-RFLP were analyzed. A higher risk for the 
5B*5B* genotypes (OR=2. 24; p=0.050) was found, at the 
expense of the cases from Patagonia, without the influence 
of the maternal genotype. Rev Arg Antrop Biol 21(1), 2019. 
doi:10.17139/raab.2019.0021.01.08
PALABRAS CLAVE N-acetiltransferasa 2; labio leporino; paladar hendido; ECLAMC
RESUMEN El labio leporino con o sin paladar hendido (NS-
CLP) es una malformación congénita que presenta las ca-
racterísticas de una patología multifactorial. Se consideran 
de especial interés los genes NAT que codifican para las N-
acetiltransferasas, enzimas responsables de la biotransfor-
mación de arilaminas, fármacos de hidrazina, y de un gran 
número de toxinas y carcinógenos presentes en la dieta, el 
humo de cigarro y el medio ambiente. Lo expuesto anterior-
mente ha despertado la sospecha de un posible rol de NAT2 
en la manifestación de LL/PH en el recién nacido expuesto. 
En este trabajo se ha evaluado la transmisión alélica de va-
riantes que determinan el fenotipo acetilador lento en 174 
tríos (caso, madre y/o padre) reclutados por el ECLAMC 
(Estudio Colaborativo Latinoamericano de Malformaciones 
Congénitas) en maternidades de Argentina. Se analizaron las 
variantes *4, *5B, *6 y *7 mediante PCR-RFLP. Se halló un 
riesgo mayor en los casos con genotipos 5B*5B* (OR=2,24; 
p=0,050), a expensas de los casos de Patagonia, sin influen-
cia del genotipo materno. Rev Arg Antrop Biol 21(1), 2019. 
doi:10.17139/raab.2019.0021.01.08
Non-syndromic cleft lip with or without cleft 
palate is a congenital condition with multifacto-
rial etiology (van Rooij et al., 2003). Its preva-
lence at birth is associated with environmental 
factors, geographical origin and socioeconomic 
conditions (Schutte and Murray, 1999). NAT2 
is involved in xenobiotic detoxification and its 
genetic expression is induced as the response 
to these compounds. Thus, a change in the ge-
netic level that affects the activity or expression 
of a gene or protein involved in the metabo-
lism of these substances can increase the risk 
of the disease. Humans can be classified as fast 
or slow acetylators based on hereditary differ-
ences in the speed of N-acetylation of therapeu-
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tic and carcinogenic agents (Krajinovic, Richer, 
Sinnett, Labuda and Sinnett, 2000). This hetero-
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geneity in N-acetyltransferase enzyme activa-
tion is called acetylation polymorphism and is 
one of the most common hereditary variations 
that affect xenobiotic metabolism. The aim of 
this work was to assess the connection between 
NAT2 genotypes for the slow acetylator pheno-
type and the risk of oral clefts.
Poletta, Castilla, Orioli and López-Camelo 
(2007) described unequal birth prevalence rate 
(BPR) among different geographic areas in 
South America through the analysis of 5128 
NSCLP cases and 3712 controls, over 4199630 
consecutive births occurred between 1967 and 
2004 in ECLAMC maternity hospitals (Castilla 
and Orioli, 1983). Expected values were cleft 
BPRs registered for the entire ECLAMC hospi-
tal network. Seven clusters for NSCLP cases of 
high BPR were identified. These clusters were 
associated with high altitude above sea level, 
Amerindian ancestry, and low socioeconomic 
strata. This work series of samples gathered two 
out of seven regions with high BPR for NSCLP, 
Northwest and Patagonia, in Argentina.
 A family-based design, with trios of case 
and parents (TCP) as an adequate method to 
assess genotype-disease association in order to 
minimize the population structure effect of the 
sample was applied.
MATERIALS AND METHODS
The cases selected showed NSCLP as their 
only anomaly. Exclusion criteria were syndromic 
cases, stillborn, and both syndromic and non-
syndromic cases born with cleft palate only. The 
sample consisted of 97 complete (case, mother 
and father) and 77 incomplete (case-mother; case-
father) trios selected from individuals from EC-
LAMC Argentine maternities (Table 1) between 
2003 and 2006. The Project was approved by the 
CEMIC Ethics Counseling Committee. Molecular 
analysis of *4 (reference allele), *5B (481C>T, 
rs1799929), *6 (590G>A, rs1799930), and *7 
(857G>A, rs1799931) alleles and their identifica-
tion were performed following a previously de-
scribed protocol (Santos, Ramallo, Muzzio, López 
Camelo and Bailliet, 2015).
In the first place, the effect of alleles as a whole, 
and after that, the effect of each allele in particular 
were analyzed. The two populations showing high 
BPR for NSCLP, Tucumán (13.0/10.000 births; 
95% CI = 12.5 - 15.7) and Patagonia (15.6 /10.000 
births; 95% CI=14.9 - 18.6), were analyzed to-
gether (“Tucumán + Patagonia”) and independ-
ently (“Tucumán” and “Patagonia”). All materni-
ties with expected BPR (10.8/10.000 births; 95% 
CI =10.4 - 11.1) values indistinguishable from the 
entire ECLAMC hospital network were called 
“Rest” (Poletta et al., 2007). Category “All” rep-
resents the total number of maternity hospitals 
analyzed.
In order to assess genotype and studied 
malformation association, a log-linear method 
for analysis of case-parent-triad data, based on 
maximum likelihood with stratification on pa-
rental mating type were used (Weinberg, 1999). 
The method leads to estimates of association 
parameters, such as relative risks, for a single 
allele, and also to likelihood ratio Chi2 tests of 
linkage disequilibrium. Hardy-Weinberg equi-
librium need not be assumed. The method gen-
eralizes easily to accommodate maternal effects 
on risk and, in fact, produces powerful and or-
thogonal tests of the contribution of fetal versus 
maternal genetic factors. Model: log(Y)= aM+ 
bF + ∑ciPM, where a estimate maternal effect, 
b fetal effect and c estimate 6 parental mating 
type effects. 
RESULTS
Allelic and genotypic frequencies and 
Hardy-Weinberg equilibrium were previ-
ously shown in Santos et al. (2015). Table 
2 shows risk alleles *5B+*6+*7 compared 
with the reference allele *4. Tables 3, 4, and 
5 shows risk alleles *5B, *6 and *7 respec-
tively. Genotypes of cases carrying two al-
leles with low metabolic rate showed risk 
in “All” category (OR=2.12; p=0.049). 
Risk was observed in categories “Pata- 
gonia” (OR=3.60; p=0.042) and “Tucumán + 
Patagonia” (OR=4.37; p=0.005) too. No risk 
was detected for “Rest” category (Table 2).
Cases included in “All” category showed 
significant risk for heterozygous (OR=1.61; 
p=0.038) and homozygous genotypes 
(OR=2.24; p=0.050) for *5B allele. For
“Patagonia”, significant risk was observed for 
heterozygous (OR=2.44; p=0.037) and ho-
mozygous genotypes (OR=5.98; p=0.044) for 
*5 allele (Table 3).
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Hospital Region City Trios Incomplete trios Complete trios
318 Metropolitan Buenos Aires 36 11 25
322 Metropolitan Buenos Aires 3 3 0
325 Metropolitan Lomas de Zamora 2 1 1
332 Metropolitan Lanús Este 3 2 1
413 Pampa Rosario 16 4 12
416 Pampa La Plata 4 1 3
418 Patagonia Bahía Blanca 9 5 4
614 Cuyo San Luis 5 4 1
803 Northwest S.M de Tucumám 37 14 23
906 Patagonia Esquel 5 3 2
907 Patagonia El Bolsón 33 18 15
909 Patagonia Bariloche 21 11 10
Total 174 77 97
TABLE 1. Complete and incomplete trios from ECLAMC maternities
S.M.: San Miguel.
 Maternities n Genotype Mother Case
OR 95% z p OR 95% z p
All 174 4/5B67* 0,74 0,37-1,49 -0,83 0,406 1,51 0,79-2,88 1,25 0,211
5B67/5B67** 0,96 0,49-1,87 -0,12 0,904 2,12 1,01-4,46 1,96 0,049 
Tucumán +  
Patagonia
96 4/5B67* 1,30 0,59-2,89 0,65 0,516 1,70 0,77-3,74 1,32 0,188
5B67/5B67** 1,65 0,71-3,83 1,17 0,242 4,37 1,55-12,35 2,78 0,005 
Tucumán 37 4/5B67* 3,97 0,83-19,03 1,73 0,084 2,18 0,41-11,50 0,92 0,359
5B67/5B67** 1,77 0,50-6,19 0,9 0,368 6,55 0,92-46,52 1,88 0,060 
Patagonia 59 4/5B67* 0,80 0,29-2,23 -0,42 0,674 1,60 0,66-3,89 1,04 0,299
5B67/5B67** 1,97 0,55-7,06 1,04 0,298 3,60 1,05-12,41 2,03 0,042 
Rest 78 4/5B67* 0,27 0,06-0,85 -1,75 0,08 1,03 0,33-3,14 0,05 0,963
5B67/5B67** 0,38 0,35-1,44 -1,43 0,153 1,06 0,32-3,57 0,10 0,918
TABLE 2.	Risk	evaluation	of	maternal	and	case	genotypes	of	174	trios,	through	a	linear	regression
model	(alleles	*5B+*6+*7)
*: Genotypes 45B, 46, and 47; **: Genotypes 5B5B, 5B6, 5B7, 66, 67, and 77; All: all maternities (803, 906, 907, 909, 325, 
322, 332, 413, 416, 418, 614); Tucumán + Patagonia:803, 906, 907, 909; Tucumán:803; Patagonia:906, 907, 909; Rest:318, 
322, 325, 332, 413, 416, 418, 614; n:number of trios.
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The analysis of allele *6 did not show risk 
genotypes in any of the categories studied (Ta-
ble 4).
For allele *7 higher risk for the hetero-
zygous genotype was found only for “Tucumán 
+ Patagonia” cases (OR=2.32; p=0.039) (Table 
5). Homozygous genotype risk for “Tucumán 
+ Patagonia” was estimated from “Patagonia” 
due to the absence of mutated homozygote in 
“Tucumán” samples.
 Maternities n Genotype Mother Case
OR 95% z p OR 95% z p
All 174 5B/467* 0,97 0,61-1,22 -0,13 0,896 1,61 1,02-2,54 2,07 0,038
5B5B 1,58 0,65-3,86 1,00 0,317 2,24 1,00-5,01 1,95 0,050 
Tucumán +
Patagonia
96 5B/467* 1,16 0,63-2,15 0,48 0,632 1,53 0,85-2,75 1,44 0,151
5B5B 3,47 0,42-28,67 1,15 0,248 2,91 0,85-9,94 1,7 0,088
Tucumán 37 5B/467* 2,21 0,64-2,21 1,26 0,208 0,75 0,29-1,93 -0,59 0,555
5B5B 0,29 0,03-3,13 1,02 0,309 1,23 0,19-7,94 0,22 0,824
Patagonia 59 5B/467* 1,08 0,46-2,23 0,02 0,984 2,44 1,06-5,57 2,09 0,037
5B5B ----- ----- ----- ----- 5,98 1,06-33,71 2,01 0,044 
Rest 78 5B/467* 0,81 0,38-1,72 -0,55 0,582 1,62 0,78-3,35 1,3 0,194
5B5B 1,02 0,34-2,98 0,01 0,990 2,10 0,69-6,41 1,3 0,194
TABLE 3. Assessment	of	maternal	and	case	risk	genotypes	in	174	trios,	through	a	linear	regression
model (risk allele:*5B)
*:Genotypes 45B, 46, and 47; All:all maternities (803, 906, 907, 909, 325, 322, 332, 413, 416, 418, 614); Tucumán + Pata-
gonia:803, 906, 907, 909; Tucumán:803; Patagonia:906, 907, 909; Rest:318, 322, 325, 332, 413, 416, 418, 614; n:number of 
trios; ----: lack of convergence in the estimate.
 Maternities n Genotype Mother Case
OR 95% z p OR 95% z p
All 174 6/45B7* 1,01 0,60-1,71 0,05 0,959 0,96 0,57-1,60 -0,16 0,870
66 0,79 0,20-3,18 -0,33 0,739 0,36 0,06-2,04 -1,15 0,250
Tucumán +Patagonia 96 6/45B7* 1,28 0,70-2,34 0,79 0,427 0,97 0,53-1,79 -0,08 0,935
66 0,86 0,12-6,14 -0,15 0,878 0,65 0,04-11,49 -0,29 0,771
Tucumán 37 6/45B7* 1,22 0,50-3,00 0,44 0,657 1,48 0,59-3,71 0,84 0,401
66 ----- ----- ----- ----- ----- ----- ----- -----
Patagonia 56 6/45B7* 1,22 0,54-2,77 0,48 0,63 0,70 0,31-1,62 -0,82 0,410
66 0,44 0,04-5,04 -0,66 0,507 0,49 0,03-9,11 -0,48 0,631
Rest 78 6/45B7* 0,60 0,21-1,70 -0,96 0,335 1.00 0,39-2,53 0,003 0,997
66 0,67 0,05-10,64 -0,26 0,797 ----- ----- ----- -----
TABLE 4.	Risk	assessment	of	genotypes	carrying	risk	allele	*6	in	mothers	and	cases,	through
linear regression.
*:Genotypes 46, 5B6, and 67; All:803, 906, 907, 909, 325, 322, 332, 413, 416, 418, 614; Tucumán + Patagonia:803, 906, 
907, 909; Tucumán:803; Patagonia:906, 907, 909; Rest:318, 322, 325, 332, 413, 416, 418, 614; n:number of trios; ----: lack 
of convergence.
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 Maternities n Genotype Mother Case
OR 95% z p OR 95% z p
All 174 7/45B6* 0,78 0,47-1,31 -0,94 0,348 1,06 0,66-1,70 0,24 0,811
77 0,88 0,19-3,96 -0,17 0,865 0,30 0,06-1,54 -1,44 0,148
Tucumán + Patagonia 96 7/45B6* 0,85 0,41-1,77 -0,44 0,663 2,32 1,04-5,15 2,07 0,039
77 1,28 0,41-1,77 0,20 0,842 2,19 0,12-40,32 0,53 0,598
Tucumán 37 7/45B6* 1,13 0,34-3,75 0,21 0,837 2,87 0,81-10,31 1,63 0,104
77 0,83 0,05-12,83 -0,14 0,89 ----- ----- ----- -----
Patagonia 56 7/45B6* 0,79 0,31-2,00 -0,5 0,615 2,10 0,76-5,79 1,43 0,153
77 ----- ----- ----- ----- 2,19 0,12-40,32 0,53 0,598
Rest 78 7/45B6* 0,77 0,37-1,61 -0,69 0,493 0,61 0,32-1,18 -1,48 0,139
77 0,82 0,10-5,75 -0,26 0,796 0,14 0,01-1,43 -1,65 0,098
TABLE 5.	Risk	assessment	of	genotypes	carrying	risk	allele	*7	in	mothers	and	cases,	through
linear regression
*:Genotypes 74, 75B, and 76; All:803, 906, 907, 909, 325, 322, 332, 413, 416, 418, 614; Tucumán + Patagonia:803, 906, 
907, 909; Tucumán:803; Patagonia:906, 907, 909; Rest:318, 322, 325, 332, 413, 416, 418, 614; n:number of trios; ----:lack 
of convergence.
This linear regression model also allows 
calculating the risk from maternal genotypes. 
Analyzing the whole “All” sample, and also 
when considering the maternities of the smaller 
groups of “Tucumán”, “Patagonia”, “Tucumán 
+ Patagonia”, and “Rest”, no maternal effect 
was found for any of the variables studied, nei-
ther pooled nor individually (Tables 2-5).
DISCUSSION
It is known that controls for a genetic study 
must be selected from the same genetic pool. 
The strategy of this paper was to recruit trios 
and dyads (case and parents) and use the geno-
typic information of the untransmitted chromo-
some of the parents as control, so as to reduce 
false positive bias due to population structure, 
adjusting for ancestry through design. 
Maternities were classified according to 
geographic clusters detected by Poletta et al. 
(2007), who identified two geographic areas in 
Argentina with high prevalence of NSCLP at 
birth: North West and Patagonia. This grouping 
allows assuming that, through a parsimony prin-
ciple, the anomaly is the result of a sole causal 
factor that compromises the cluster specifically.
To assess the association between presence 
of NSCLP and genotypes that determine the 
slow acetylator phenotype, variants *5B, *6, and 
*7 were considered, combining trios from all 
maternities in detriment of genetic homogene-
ity. For the whole sample, a significant risk was 
found, twice higher for NSCLP when the fetal 
genotype was homozygous for the risk alleles. 
Particularly, significant risk for “Tucumán” and 
“Patagonia” cases for genotypes with 2 risk al-
leles was found. “Tucumán” showed the highest 
risk but no statistical difference, probably due 
to the low number of trios in that region (type β 
error) (Table 2). 
The risk of allelic variants *5B, *6, and *7 
individually was evaluated. Allele *5B showed 
association for the “All” category (heterozy-
gotes, OR=1.61; p=0.038; and homozygotes, 
OR=2.24; p=0.050), and for “Patagonia”
(heterozygotes, OR=2.44; p=0.037; and ho-
mozygotes OR=5.98; p=0.044), thus “Patago-
nia” is responsible for the increased risk in the 
“All” group. No association was observed be-
tween NSCLP and allele *6. Regarding variant 
*7, a risk for heterozygous genotypes (OR=2.32; 
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p=0.039) was found only in “Tucumán + Pa-
tagonia” group. So, variants *5B and *7 but 
not *6 are responsible for the estimated risk for 
SNPs *5B+*6+*7 among “All” (Table 2). In 
“Patagonia” cases, *5B allele is responsible for 
the risk, while in “Tucumán” *7 is. 
Several studies have reported a correlation 
between high frequency of slow aceltylators 
in human populations practising subsistence 
farming, which suggests that a slower rate of 
acetylation may have gained selective advan-
tage in populations shifting from foraging to ag-
riculture during the Neolithic period. The same 
was observed for American hunter-gathering 
populations in which NAT2*4 was predomi-
nant and NAT2*5B and NAT2*7B tended to be 
higher for agricultural populations (Luca et al., 
2008; Sabbagh, Darlu, Crouau-Roy and Poloni, 
2010). This is the case of the Northwest in the 
present work, region that has been occupied by 
agricultural populations since 8000 years BP, 
while Patagonia inhabitants displayed hunter-
gathering subsistence strategies until the arrival 
of Europeans in Argentina. While NAT2*4 was 
predominant in Patagonian populations with 
frequencies of 40% or more, in the Northwest 
it was 30%. For the rest of the hospital cases, 
the effect of migration could have probably pro-
duced intermediate frequencies of each genetic 
variation (Santos et al., 2015, present work). 
These genetic backgrounds would be responsi-
ble for the differentiation between the two areas 
with high birth rate prevalence, Northwest and 
Patagonia.     
The linear regression model also allows in-
ferring the relative importance of maternal gen-
otypes in the causality of the anomaly studied. 
Using this test, no maternal effect could be de-
tected for any of the variants analyzed, neither 
individually nor pooled. Moreover, Lie et al. 
(2008) did not find maternal effect in a sample 
of 314 trios from Norway (OR=1.00; IC=0.5-
1.8). Interestingly, Shi et al. (2007) showed a 
20% higher risk of anomaly when the mother 
carried a risk allele (p=0.03). 
Other association studies on the same allelic 
variants and NSCLP are discordant (Birnbaum 
et al., 2009; Lammer, Iovannisci, Van Waes and 
Finnell, 2004; Lie et al., 2008; Marazita et al., 
2004; Shi et al., 2007). Using the same Patago-
nia sample population as the one in the present 
work, from a complex segregation study Polet-
ta (2010) suggested that the effect of the main 
gene for NSCLP could be modified by another 
locus and/or factor of environmental exposure. 
This main dominant gene would have low pen-
etrance (6 to 15%) and the frequency of the risk 
allele would be between 1 and 9%, added to a 
multifactorial component (or residual variance 
unexplained by the main gene). Another finding, 
relevant to the interpretation of our results and 
key in the study of NSCLP, was the contribu-
tion of IRF6 to NSCLP (Zucchero et al., 2004). 
Authors analyzed 8003 individuals from 1,968 
families from Asian, European and American 
populations. This work showed that all genes 
that contribute to the anomaly have a very low 
effect compared to IRF6’s in NSCLP. Regarding 
segregation studies, evidence reported by Poletta 
(2010) and Zuchero et al. (2004) demonstrated 
that NAT2 is neither a necessary nor sufficient 
factor for NSCLP. Nevertheless, some involve-
ment in cleft occurrence due their metaboli- 
zing function cannot be ruled out as part of this 
multifactorial component or residual variance 
unexplained by the main gene. Clearly, the high 
proportion of NSCLP cases is a result of other 
etiological agents, unassociated to these alleles.
CONCLUSION
The present work, through a family-based 
case-control design, confirms the association 
between the allele *5B, that determines the 
slow acetylator phenotype, and the occurrence 
of the NSCLP. This allelic variant could act as 
a marker in linkage disequilibrium of causal 
haplotypes. As markers, some NAT2 SNPs 
could be more informative in some human pop-
ulations than in others and this could explain 
some discrepancies in the association results. 
Likewise, no participation of NAT2 can be dis-
regarded in the generation of NSCLP as part of 
the multivariate component or residual variance 
not explained by the main gene.
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